BioCentury | Mar 11, 2013
Clinical News

Ibudilast regulatory update

...FDA granted Fast Track designation for ibudilast to treat methamphetamine dependence. The phosphodiesterase-4 (PDE-4) , leukotriene B4 receptor...
BioCentury | Dec 10, 2012
Clinical News

Ibudilast: Phase IIa started

...MN-166/AV411 ) Business: Neurology Molecular target: Phosphodiesterase-4 (PDE-4) ; Leukotriene B4 receptor Description: Inhibits phosphodiesterase-4 (PDE-4), leukotriene B4 receptor...
BioCentury | Sep 17, 2012
Clinical News

Ibudilast: Phase II start

...MN-166/AV411 ) Business: Neurology Molecular target: Phosphodiesterase-4 (PDE-4) ; Leukotriene B4 receptor Description: Inhibits phosphodiesterase-4 (PDE-4), leukotriene B4 receptor...
BioCentury | Apr 14, 2011
Distillery Therapeutics

Indication: Cancer

...steps include testing PDE-4 inhibitors in mouse models of Ras-dependent melanoma. Ketas ibudilast, a PDE-4, leukotriene B4 receptor...
BioCentury | Dec 10, 2009
Distillery Therapeutics

Indication: Musculoskeletal disease

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair; osteoporosis Leukotriene B4 receptor (LTB4R...
BioCentury | Jan 5, 2009
Company News

Avigen, Baxter, MediciNova deal

...Nov. 10, 2008). MediciNova's lead compound is MN-166 , an inhibitor of phosphodiesterase-4 (PDE-4) , leukotriene B4 receptor...
BioCentury | Dec 24, 2008
Company News

MediciNova bids for Avigen

...to Baxter (NYSE:BAX). MediciNova's lead compound is MN-166 , an inhibitor of phosphodiesterase-4 (PDE-4) , leukotriene B4 receptor...
BioCentury | Nov 17, 2008
Analyst Picks & Changes

Analyst picks & changes

...of greater dilution. Last year, the company reported that MN-166, an inhibitor of phosphodiesterase-4 (PDE-4), leukotriene B4 receptor...
BioCentury | Apr 14, 2008
Clinical News

Ibudilast: Additional Phase II data

...MN-166 ) Business: Autoimmune Molecular target: Phosphodiesterase-4 (PDE-4) ; Leukotriene B4 receptor Description: Inhibits phosphodiesterase-4 (PDE-4), leukotriene B4 receptor...
BioCentury | Apr 7, 2008
Clinical News

Ibudilast: Additional Phase II data

...MN-166 ) Business: Autoimmune Molecular target: Phosphodiesterase-4 (PDE-4) ; Leukotriene B4 receptor Description: Inhibits phosphodiesterase-4 (PDE-4), leukotriene B4 receptor...
Items per page:
1 - 10 of 23